Users online: 2181    [ij] [ij] [ij] 
Email id

Year : 2021, Volume : 14, Issue : 2
First page : ( 1041) Last page : ( 1044)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2021.00186.4

Deferiprone (Ferriprox) as newer iron chelator in thalassaemia major patients

Chaudhary Jinal L.*, Rathi Sanjesh G, Shah Sanket, Patel Jigna T, Vaghela Sohansinh

Department of Pharmacy, Practice Saraswati Institute of Pharmaceutical Sciences, Dhanap, Ghandhinagar.

*Corresponding Author E-mail: jinalc95@gmail.com

Online published on 30 April, 2021.


The present study was on Deferiprone is the first line therapy in treatment of thalassemia patients either alone or in combination with other available chelating agents. Advantage over other iron chelators is, oral mode of administration, better compliance, being more affordable, similar efficacy in reducing iron burden in patients with severe haemosiderosis. Long-term Deferiprone therapy is generally well tolerated, and a longer duration of therapy is warranted in patients with severe iron overload. Deferiprone offers an acceptable second line alternative. Patients with thalassemia major for whom deferoxamine therapy is contra-indicated or who present serious toxicity with deferoxamine therapy. A comparison between the pre-clinical data and the safety data is very difficult in this case. The most important adverse reactions are agranulocytosis and neutropenia whose incidence is 1.2% and 6% respectively. The amount of long-term data is limited, but in view of the indication this was accepted. As a weekly monitoring of blood counts is accepted for the safety of the product.



Deferiprone, Thalassemia, Haemosiderosis, Deferoxamine.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
625,893,402 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.